Inside the Virtual Aging Cell: How Insilico Medicine's Multi-Agent Platform Simulates Aging Across Six Biological Scales

VAC represents the next step beyond Precious3GPT — a multi-agent platform that coordinates these AI capabilities to simulate aging at the cell level rather than simply predicting ages or generating omics profiles .

Clinical Pipeline: Rentosertib and the AI-Discovered Drug Portfolio

Rentosertib (ISM001-055) — A first-in-class AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis (IPF). The Phase IIa GENESIS-IPF trial, a randomized, double-blind, placebo-controlled study across 22 sites in China, showed manageable safety and tolerability, with the 60 mg once-daily arm demonstrating a mean forced vital capacity improvement of +98.4 mL at 12 weeks, compared to a mean decline of -20.3 mL in the placebo group . Results were published in Nature Medicine (Impact Factor 58.7) and presented at the American Thoracic Society (ATS) 2025 International Conference . Phase IIa is completed, and Insilico initiated a Phase III trial in July 2026, with first patient enrollment expected by September 2025, last patient by November 2028, and initial results expected by December 2029 . An inhalation solution of Rentosertib also received IND clearance from the China National Medical Products Administration (CDE) in April 2026 .

ISM6331 — A novel AI-designed pan-TEAD inhibitor for unresectable malignant pleural mesothelioma. The FDA granted Fast Track Designation on July 29, 2026 — Insilico's first FTD — for adult patients whose disease progressed after prior anti-PD-1 antibody therapy, with or without anti-CTLA-4 therapy, and platinum-based chemotherapy . First-in-human Phase I trial data have been accepted for a rapid oral presentation at the ESMO 2026 conference in Madrid .

Important Caveat: VAC Remains a Technology Preview

It is critical to note that the VAC platform is a technology preview, not a fully validated system. The company's own webpage labels it as "in development" and frames it as an industry-first demonstration of concept rather than a validated, deployed tool . No peer-reviewed validation studies for VAC itself have been published to date . The platform allows users to explore the concept and provide feedback, but it has not yet undergone the rigorous validation that would be required for regulatory or clinical use.

Broader Context: Aging as a Drug Discovery Lens

Insilico's approach is rooted in the idea that aging is the underlying driver of many diseases. "Using aging as a way to identify disease, Insilico has trained AI to do what it does best — take large amounts of data from many components to identify new targets and new molecules," the company states . By embedding biological age as a core parameter in the VAC platform, the company aims to create a unified computational framework where aging biology serves as the foundation for identifying interventions that could modulate both aging and age-related diseases .

The VAC platform represents a significant conceptual advance in computational biology, but its practical utility remains to be demonstrated through peer-reviewed validation and independent replication.